About: R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition
Creator	Gouglas, Dimitrios Røttingen, John-Arne Gopinathan, Unni Ottersen, Trygve Peacocke, Elizabeth
Source	PMC
abstract	The lack of effective vaccines for emerging infectious diseases (EID) of limited market potential, such as Chikungunya and Zika, poses a serious threat to human life and prosperity. Research and development (R&D) for new vaccines for EIDs faces two major challenges. The first is R&D preparedness: that is, to advance EID vaccine candidates to the latest R&D stage possible during non-epidemic times, on the basis of any feasible safety or efficacy data. The second is R&D response: that is, to test the clinical efficacy of vaccine candidates rapidly once an outbreak erupts. To overcome these challenges, the Coalition for Epidemic Preparedness Innovations (CEPI) was established in August 2016. Here, we explore why the realisation of CEPI’s mission—preventing outbreaks of emerging infectious diseases from becoming humanitarian crises—is a global public good, and the crucial role R&D preparedness and R&D response play in providing this good. We next examine why providing this global public good requires incentivising involvement and sharing risks with the private sector. Finally, we explore the potential for CEPI to be an agent mobilising shared responsibilities, including key factors that must be addressed in order for CEPI to demonstrate to governments that collective action is the preferred strategy for preventing future epidemics and strengthening global health security.
has issue date	2020-05-16(xsd:dateTime)
bibo:doi	10.1007/978-3-030-39819-4_7
has license	no-cc
sha1sum (hex)	05ea974f4ce5ade42c634ddcbceed6323e3ef6f5
schema:url	https://doi.org/10.1007/978-3-030-39819-4_7
resource representing a document's title	R&D for Emerging Infectious Diseases of Epidemic Potential: Sharing Risks and Benefits Through a New Coalition
has PubMed Central identifier	PMC7226903
schema:publication	Infectious Diseases in the New Millennium
resource representing a document's body	covid:05ea974f4ce5ade42c634ddcbceed6323e3ef6f5#body_text
is schema:about of	named entity 'Coalition' named entity 'prosperity' named entity 'security' named entity 'emerging infectious diseases' named entity 'factors' named entity 'order' named entity '2016' named entity 'agent' named entity 'ESTABLISHED' named entity 'AUGUST' named entity 'PRIVATE SECTOR' named entity 'STRATEGY' named entity 'HUMAN LIFE' named entity 'PLAY' named entity 'INVOLVEMENT' named entity 'STRENGTHENING' named entity 'LACK' named entity 'COALITION' named entity 'THESE' named entity 'EPIDEMIC' named entity 'potential' named entity 'EIDs' named entity 'explore' named entity 'outbreaks' named entity 'collective action' named entity 'disease burden' named entity 'Creative Commons Attribution 4.0' named entity 'Indonesia' named entity 'civil society' named entity 'CEPI' named entity 'CEPI' named entity 'CEPI' named entity 'India' named entity 'decision-making' named entity 'Canada' named entity 'mass vaccination' named entity 'vaccine' named entity 'PDPs' named entity 'global public goods' named entity 'WHO' named entity 'public health' named entity 'non-excludability' named entity 'global public goods' named entity 'epidemic' named entity 'Sanofi Pasteur' named entity 'International Health Regulations' named entity 'HIV/AIDS' named entity 'Phase 1' named entity 'data sharing' named entity 'Ebola outbreak' named entity 'vaccine' named entity 'Morrissey' named entity 'phase 3 trials' named entity 'pandemics' named entity 'Ebola outbreak in 2014' named entity 'R&D' named entity 'health technology' named entity 'vaccination' named entity 'CEPI' named entity 'Innovations' named entity 'CEPI' named entity 'test' named entity 'limited' named entity 'clinical trials' named entity 'influenza vaccine' named entity 'Annex 1' named entity 'high-income' named entity 'World Health Organisation' named entity 'universal health coverage' named entity 'Ebola vaccine' named entity 'viruses' named entity 'public good' named entity 'CEPI' named entity 'Sierra Leone' named entity 'epidemic' named entity 'Health in Guinea' named entity 'CEPI' named entity 'smallpox' named entity 'public-private partnerships'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software